Summary: In 32 adults with obesity and prediabetes or newly diagnosed type 2 diabetes, weight loss achieved by either liraglutide or lifestyle counselling produced a significant but comparable fall in IL-1β and in MASLD severity (p for between-arm difference = 0.56). Baseline IL-1β independently predicted the extent of MASLD improvement (p = 0.030), with the lowest IL-1β tertile showing the largest steatosis reduction.
PICO Summary
| Element | Detail |
|---|---|
| Population | 32 adults with obesity and either prediabetes (n=16) or newly diagnosed type 2 diabetes (n=16); randomized controlled trial, single centre, Italy. |
| Intervention | Liraglutide (GLP-1 receptor agonist) titrated to a target weight loss; one randomized arm. |
| Comparison | Lifestyle counselling titrated to a comparable weight loss; the other randomized arm. There was no untreated control group. |
| Outcome | IL-1β expression in peripheral blood mononuclear cells fell significantly but comparably in both arms (p for difference = 0.56), alongside comparable improvements in glycaemic control, CRP, BMI and MASLD. Baseline IL-1β independently predicted the extent of MASLD decrease (p = 0.030): highest tertile median change -8.0 (95% CI -12.3 to -4.8) versus -23.0 (95% CI -39.5 to -16.3) in the lowest tertile. No significance testing established an efficacy difference between liraglutide and lifestyle; the between-arm comparison was null. |
Expert Commentary
This small randomized trial is best read as a biomarker and mechanistic study rather than a treatment comparison. Its central, internally consistent message is that the inflammatory cytokine IL-1β tracks metabolic burden and that successful weight loss, however achieved, lowers it in parallel with steatosis. The headline that liraglutide and lifestyle produced comparable reductions is a deliberately null between-arm result (p for difference = 0.56), engineered by titrating both arms to the same weight loss target; it should not be reported as one intervention outperforming another. The more provocative observation is that baseline IL-1β independently predicted the magnitude of MASLD improvement, raising the possibility of a response biomarker. The principal limitation is sample size: with only 32 participants split across two arms and three tertiles, the predictive estimates are imprecise and exploratory, and the trial cannot be blinded because a drug is compared against counselling, leaving open-label expectation effects. Can I use this with my patients? Not yet. There is no validated IL-1β assay or threshold to guide who should be offered which weight-loss strategy, and these findings are hypothesis-generating. Larger, adequately powered studies should test whether baseline IL-1β truly enriches for liver responders before this enters clinical decision-making.
References
Simeone PG, Costantino S, Liani R, Tripaldi R, Di Castelnuovo A, Tartaro A, et al. Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):247. doi:10.1186/s12933-025-02706-8